BANGALORE Dec 13 (Reuters) - Shares of Nektar Therapeutics (NKTR.O) fell as much as 7 percent after the company said it will not seek a partner for its key cancer drug that showed promise in a mid-stage trial, raising concerns over its ability to finance the drug’s development.
